The lab firm said it now expects full-year net revenue in the range of $11.95 billion to $12.05 billion, up from its previous guidance of $11.78 billion to $11.90 billion.

The IVDR encompasses the firm's ER, PR, and Ki67 testing and completes certification of its overall digital pathology breast suite.

Precision Diabetes said on Thursday that it has acquired the exclusive US commercial rights to Nagase Diagnostics' Lucica Glycated Albumin-L assay for diabetes management. Financial and other terms of ...

The second generation test can detect the Bundibugyo strain of the virus that currently poses a threat in the Democratic Republic of the Congo and nearby countries.

The tests will help identify the inflammatory pathways involved in patients with COPD and asthma to help better guide therapy selection.

According to DOJ, the company provided consulting services at below market value to certain health care providers that referred patients to NeoGenomics for lab testing.

The firm is developing blood-based early cancer detection tests for a variety of indications, including colorectal cancer and lung cancer.

Abbott said on Thursday that its second quarter Diagnostics sales grew 42 percent to $3.09 billion compared to $2.17 billion in the year-ago quarter, helped along by its acquisition of Exact Sciences ...

The tests are intended for infectious and chronic disease detection and diagnosis as well as to aid in routine health monitoring.

NEW YORK – The Centers for Medicare & Medicaid Services issued a request for information Thursday seeking public input on potential updates to the Clinical Laboratory Improvement Amendments of 1988 ...

Burning Rock will add the prostate Genomic Instability Score (prGIS) algorithm to its myChoice HRD Plus assay and will develop new HRD tests on its OncoScreen Plus platform.